Medical Director, MD
Ascendis Pharma A/S · Alkermes, Inc. · Endo USA Inc., a Keenova Therapeutics Company
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Medical Director, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:32 UTC. Showing 200 of 227. Open this list on ClinicalTrials.gov
- Ph3NCT07924059 · Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in AchondroplasiaAscendis Pharma A/S · not yet recruiting · Achondroplasia · study director
- Ph3NCT07917143 · A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With HypochondroplasiaAscendis Pharma A/S · not yet recruiting · Hypochondroplasia · study director
- Ph2NCT07901179 · A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive DisorderAlkermes, Inc. · recruiting · Major Depressive Disorder (MDD) · study director
- Ph3NCT07846280 · Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT)Endo USA Inc., a Keenova Therapeutics Company · not yet recruiting · Flexible Hammertoe, Semi-flexible Hammertoe · study director
- Ph3NCT07759362 · Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)Endo USA Inc., a Keenova Therapeutics Company · recruiting · Flexible Hammertoe, Semi-flexible Hammertoe · study director
- Ph2NCT07755410 · A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)Alkermes, Inc. · recruiting · Attention Deficit Disorder With Hyperactivity (ADHD) · study director
- Ph3NCT07706764 · A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismAscendis Pharma A/S · recruiting · Hypoparathyroidism · study director
- Ph3NCT07540897 · A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)Alkermes, Inc. · recruiting · Narcolepsy Type 1 · study director
- Ph4NCT07477691 · Immune Modulation During Palynziq® Treatment in Adults (IMPALA)BioMarin Pharmaceutical · recruiting · Phenylketonuria · study director
- Ph3NCT07473973 · ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 DeficiencyInozyme Pharma · terminated · Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy 1 · study director
- Ph3NCT07455383 · A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1Alkermes, Inc. · recruiting · Narcolepsy Type 1 · study director
- N/ANCT07345494 · A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and BreastfeedingAscendis Pharma A/S · recruiting · Hypoparathyroidism · study director
- N/ANCT07264634 · A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)Ascendis Pharma A/S · recruiting · Hypoparathyroidism · study director
- Ph3NCT07221851 · Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersAscendis Pharma A/S · recruiting · Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature · study director
- Ph2NCT07209332 · Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences USA, Inc. · enrolling by invitation · Duchenne Muscular Dystrophy · study director
- Ph1/Ph2NCT07172646 · A Study of SRSD216 in Patients With Elevated Lipoprotein (a)Sirius Therapeutics Co., Ltd. · recruiting · Hyperlipoproteinemia (a) · study director
- Ph3NCT07085767 · Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerOlema Pharmaceuticals, Inc. · recruiting · Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer · study director
- Ph3NCT07081997 · A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With HypoparathyroidismAscendis Pharma Bone Diseases A/S · recruiting · Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases · study director
- Ph2NCT06972628 · Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617Ebrahim S Delpassand · recruiting · Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis, Prostate Cancer (CRPC) · principal investigator
- Ph1/Ph2NCT06842186 · A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or ObesityWave Life Sciences USA, Inc. · recruiting · Overweight and Obesity · study director
- Ph4NCT06780332 · Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to PalynziqBioMarin Pharmaceutical · completed · Phenylketonuria, PKU · study director
- Ph1NCT06738017 · Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult ParticipantsBioMarin Pharmaceutical · active not recruiting · Alpha 1-Antitrypsin Deficiency · study director
- Ph2NCT06732895 · A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Ascendis Pharma A/S · active not recruiting · Achondroplasia · study director
- N/ANCT06698731 · A Randomized, Active-Controlled, Double-Masked, Crossover Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens for Presbyopia Extended Depth of Focus (EDOF)Bruno Vision Care · completed · Presbyopia Condition · study director
- Ph2NCT06668805 · A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentBioMarin Pharmaceutical · active not recruiting · Noonan Syndrome · study director
- Ph2NCT06555783 · A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2Alkermes, Inc. · completed · Narcolepsy Type 2 · study director
- Ph3NCT06455059 · Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaBioMarin Pharmaceutical · active not recruiting · Hypochondroplasia · study director
- Ph2NCT06433557 · A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaAscendis Pharma Growth Disorders A/S · active not recruiting · Achondroplasia · study director
- Ph1/Ph2NCT06405633 · A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATDWave Life Sciences USA, Inc. · recruiting · Alpha-1 Antitrypsin Deficiency · study director
- Ph2NCT06382155 · A Phase 2 Study of Vosoritide in Children With Idiopathic Short StatureBioMarin Pharmaceutical · recruiting · Idiopathic Short Stature
- Ph2NCT06358950 · A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)Alkermes, Inc. · completed · Narcolepsy Type 1 · study director
- N/ANCT06305234 · A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)BioMarin Pharmaceutical · recruiting · Phenylketonuria (PKU) · study director
- N/ANCT06290206 · PREVENT HPV-Related Cancers - BootCamp TranslationUniversity of Utah · completed · HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion · study chair
- N/ANCT06212947 · A Multicenter Multinational Observational Study of Children With HypochondroplasiaBioMarin Pharmaceutical · recruiting · Hypochondroplasia · study director
- N/ANCT06168201 · VIrtual STudy in Achondroplasia for the US (VISTA)BioMarin Pharmaceutical · recruiting · Achondroplasia · study director
- Ph1NCT06138327 · A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And HyperoxaluriaBioMarin Pharmaceutical · withdrawn · Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone · study director
- Ph2NCT06079398 · A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaAscendis Pharma A/S · recruiting · Achondroplasia · study director
- Ph3NCT06016738 · OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerOlema Pharmaceuticals, Inc. · active not recruiting · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer · study director
- Ph2/Ph3NCT05929807 · A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With AchondroplasiaAscendis Pharma Growth Disorders A/S · enrolling by invitation · Achondroplasia · study director
- N/ANCT05820672 · A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFAAscendis Pharma Endocrinology Division A/S · recruiting · Growth Hormone Deficiency · study director
- N/ANCT05813678 · A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)BioMarin Pharmaceutical · recruiting · Phenylketonuria (PKU) · study director
- N/ANCT05775523 · A Post-Authorisation Safety Study (PASS) of Patients Treated With LonapegsomatropinAscendis Pharma Endocrinology Division A/S · recruiting · Growth Hormone Deficiency · study director
- N/ANCT05768386 · A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)BioMarin Pharmaceutical · enrolling by invitation · Hemophilia A · study director
- Ph1NCT05734196 · The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 DeficiencyInozyme Pharma · terminated · Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy · study director
- Ph1/Ph2NCT05683860 · Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)Wave Life Sciences USA, Inc. · terminated · Amyotrophic Lateral Sclerosis, Frontotemporal Dementia · study director
- Ph2/Ph3NCT05598320 · A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With AchondroplasiaAscendis Pharma Growth Disorders A/S · completed · Achondroplasia · study director
- N/ANCT05579548 · A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and BreastfeedingBioMarin Pharmaceutical · recruiting · Phenylketonuria, Maternal · study director
- Ph1NCT05477095 · A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy ParticipantsAxxium Life, Inc. · completed · Migraine · study director
- Ph1/Ph2NCT05032196 · Study of WVE-003 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · completed · Huntington Disease · study director
- Ph1/Ph2NCT05030831 · Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXEInozyme Pharma · completed · ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum, Generalized Arterial Calcification of Infancy · study director
- Ph3NCT05001737 · Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLESwedish Orphan Biovitrum · completed · Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease · study director
- Ph1NCT04996030 · A Study for Oral SY-2101 for Participants With Acute Promyelocytic LeukemiaSyros Pharmaceuticals · suspended · Acute Promyelocytic Leukemia · study director
- Ph1/Ph2NCT04931862 · Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)Wave Life Sciences USA, Inc. · terminated · ALS, FTD · study director
- Ph1/Ph2NCT04906460 · Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)Wave Life Sciences USA, Inc. · active not recruiting · Duchenne Muscular Dystrophy · study director
- Ph2NCT04905407 · Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)Syros Pharmaceuticals · terminated · Acute Myeloid Leukemia · study director
- Ph1/Ph2NCT04686175 · Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 DeficiencyInozyme Pharma · completed · Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy · study director
- Ph3NCT04624204 · Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Merck Sharp & Dohme LLC · active not recruiting · Small Cell Lung Cancer · study director
- Ph1/Ph2NCT04617860 · Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · terminated · Huntington Disease · study director
- Ph1/Ph2NCT04617847 · Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · terminated · Huntington Disease · study director
- Ph3NCT04615273 · A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone DeficiencyAscendis Pharma Endocrinology Division A/S · completed · Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency · study director
- Ph2NCT04583423 · A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)Merck Sharp & Dohme LLC · terminated · Nonalcoholic Steatohepatitis · study director
- Ph2NCT04554940 · A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With AchondroplasiaBioMarin Pharmaceutical · active not recruiting · Achondroplasia · study director
- Ph1/Ph2NCT04480567 · AAV Gene Therapy Study for Subjects with PKUBioMarin Pharmaceutical · active not recruiting · Phenylketonuria (PKU) · study director
- N/ANCT04476862 · Cerliponase Alfa Observational Study in the USBioMarin Pharmaceutical · active not recruiting · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 · study director
- Ph1NCT04075318 · Study of UB-312 in Healthy Participants and Parkinson's Disease PatientsUnited Neuroscience Ltd. · completed · Parkinson's Disease, Parkinsonism · study director
- Ph2NCT04009291 · A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismAscendis Pharma A/S · completed · Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases · study director
- Ph2NCT03989947 · An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaBioMarin Pharmaceutical · active not recruiting · Achondroplasia
- N/ANCT03864029 · Retrospective Observational Safety Effectiveness With Kuvan in hpABioMarin Pharmaceutical · completed · Tetrahydrobiopterin Deficiency · study director
- Ph3NCT03694353 · Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKUBioMarin Pharmaceutical · completed · Phenylketonuria (PKU) · study director
- Ph2NCT03583697 · A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With AchondroplasiaBioMarin Pharmaceutical · completed · Achondroplasia · study director
- Ph1/Ph2NCT03520712 · Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5BioMarin Pharmaceutical · terminated · Hemophilia A, Gene Therapy, Clotting Disorders · study director
- N/ANCT03505125 · A Non-Interventional Interview Study of Phenylketonuria (PKU) AdultsBioMarin Pharmaceutical · completed · Phenylketonuria (PKU) · study director
- Ph3NCT03392974 · Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgBioMarin Pharmaceutical · completed · Hemophilia A · study director
- Ph3NCT03344458 · A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical TrialAscendis Pharma A/S · completed · Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency · study director
- N/ANCT03227042 · A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)Allievex Corporation · unknown · Mucopolysaccharidosis Type IIIB · study director
- Ph1/Ph2NCT03225846 · Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · terminated · Huntington's Disease · study director
- Ph1/Ph2NCT03225833 · Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · terminated · Huntington's Disease · study director
- Ph3NCT03197766 · A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaBioMarin Pharmaceutical · completed · Achondroplasia · study director
- Ph2NCT03033108 · Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt DiseaseKubota Vision Inc. · completed · Stargardt Disease, Macular Atrophy · study director
- Ph2NCT02724228 · A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)BioMarin Pharmaceutical · active not recruiting · Achondroplasia · study director
- Ph2NCT02678689 · A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 DiseaseBioMarin Pharmaceutical · completed · Jansky-Bielschowsky Disease, Batten Disease, Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 · study director
- Ph1/Ph2NCT02576795 · Gene Therapy Study in Severe Haemophilia A Patients (270-201)BioMarin Pharmaceutical · completed · Severe Haemophilia A · study director
- Ph2/Ph3NCT02564588 · Dasotraline Binge Eating Disorder StudySumitomo Pharma America, Inc. · completed · Binge Eating Disorder · study director
- Ph2/Ph3NCT02428088 · Dasotraline Pediatric ADHD StudySumitomo Pharma America, Inc. · completed · Attention Deficit Hyperactivity Disorder · study director
- Ph2NCT02399137 · A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic CancerMerrimack Pharmaceuticals · completed · Pancreatic Cancer · study director
- Ph2NCT02387216 · A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLCElevation Oncology · terminated · Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma · study director
- Ph3NCT02347761 · Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPDSunovion Respiratory Development Inc. · completed · COPD · study director
- Ph3NCT02347774 · Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)Sunovion Respiratory Development Inc. · completed · COPD, Chronic Obstructive Pulmonary Disease · study director
- Ph1NCT02320032 · An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable SchizophreniaAlkermes, Inc. · completed · Schizophrenia · study director
- N/ANCT02294877 · A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)BioMarin Pharmaceutical · completed · Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA · study director
- Ph3NCT02276209 · Dasotraline Adult ADHD StudySumitomo Pharma America, Inc. · completed · Adult Attention Deficit Hyperactivity Disorder · study director
- Ph4NCT02275481 · A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) SubjectsSumitomo Pharma America, Inc. · terminated · Chronic Obstructive Pulmonary Disease (COPD) · study director
- Ph1NCT02195167 · Dasotraline SEP360-105 Pediatric PK/PD StudySumitomo Pharma America, Inc. · completed · Pediatric Attention Deficit Hyperactivity Disorder · study director
- Ph3NCT02150499 · A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric SubjectsSumitomo Pharma America, Inc. · terminated · Asthma · study director
- Ph2NCT02092077 · A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient ChildrenTeva Pharmaceutical Industries, Ltd. · terminated · Growth Hormone-Deficiency · study director
- Ph2NCT02055157 · A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With AchondroplasiaBioMarin Pharmaceutical · completed · Achondroplasia · study director
- Ph3NCT02046369 · Lurasidone Pediatric Bipolar StudySumitomo Pharma America, Inc. · completed · Bipolar I Depression · study director
- Ph3NCT02040779 · A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent AsthmaTeva Branded Pharmaceutical Products R&D, Inc. · completed · Persistent Asthma · study director
- Ph2NCT02038829 · A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPDSunovion Respiratory Development Inc. · completed · COPD · study director
- Ph1NCT02030457 · A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy AdultsTeva Branded Pharmaceutical Products R&D, Inc. · completed · Pharmacokinetics · study director
- Ph3NCT01975298 · A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)Teva Branded Pharmaceutical Products R&D, Inc. · withdrawn · Relapsing Remitting Multiple Sclerosis · study director
- Ph2NCT01947907 · Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)Ascendis Pharma A/S · completed · Growth Hormone Deficiency (GHD) · study director
- Ph3NCT01914393 · Pediatric Open-Label Extension StudySumitomo Pharma America, Inc. · completed · Schizophrenia, Autism, Bipolar Depression · study director
- Ph3NCT01911442 · Lurasidone Pediatric Autism StudySumitomo Pharma America, Inc. · completed · Autism · study director
- Ph3NCT01829464 · TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 DiabetesTakeda · terminated · Diabetes · study director
- Ph3NCT01710631 · Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With InsomniaSumitomo Pharma America, Inc. · completed · Primary Insomnia · study director
- Ph2NCT01706536 · A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseSunovion Respiratory Development Inc. · completed · COPD · study director
- Ph3NCT01704261 · Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)Merck Sharp & Dohme LLC · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT01692782 · Adult Attention Deficit Hyperactivity DisorderSumitomo Pharma America, Inc. · completed · Adult Attention Deficit Hyperactivity Disorder · study director
- Ph2NCT01656811 · A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With AsthmaSumitomo Pharma America, Inc. · completed · Asthma · study director
- Ph4NCT01654536 · A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)Sumitomo Pharma America, Inc. · completed · Perennial Allergic Rhinitis · study director
- N/ANCT01603095 · A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With AchondroplasiaBioMarin Pharmaceutical · completed · Achondroplasia · study director
- Ph3NCT01575561 · This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296Sumitomo Pharma America, Inc. · completed · Bipolar I Disorder · study director
- Ph3NCT01566162 · A Twelve Week, Open Label Extension Study in Patients With SchizophreniaSumitomo Pharma America, Inc. · completed · Schizophrenia · study director
- Ph1NCT01493726 · A Study of ALKS 9072 in Subjects With Chronic Stable SchizophreniaAlkermes, Inc. · completed · Schizophrenia · study director
- Ph3NCT01485640 · Lurasidone Extended Use StudySumitomo Pharma America, Inc. · completed · Schizophrenia, Bipolar Disorder · study director
- Ph3NCT01458275 · A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)Sumitomo Pharma America, Inc. · completed · Seasonal Allergic Rhinitis · study director
- Ph3NCT01451541 · A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).Sumitomo Pharma America, Inc. · completed · Perennial Allergic Rhinitis, PAR · study director
- Ph4NCT01438801 · Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)Ipsen · withdrawn · Idiopathic Short Stature · study director
- Ph3NCT01435928 · PEARL Schizophrenia MaintenanceSumitomo Pharma America, Inc. · completed · Schizophrenia · study director
- Ph3NCT01423253 · Major Depressive Disorder With Mixed Features - ExtensionSumitomo Pharma America, Inc. · completed · Major Depressive Disorder · study director
- Ph3NCT01423240 · Major Depressive Disorder With Mixed FeaturesSumitomo Pharma America, Inc. · withdrawn · Major Depressive Disorder · study director
- Ph3NCT01421134 · Major Depressive Disorder (MDD) With Mixed Features - Flexible DoseSumitomo Pharma America, Inc. · completed · Major Depressive Disorder With Mixed Features · study director
- Ph3NCT01358357 · Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexSumitomo Pharma America, Inc. · completed · Bipolar I Disorder · study director
- Ph3NCT01284517 · Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I DepressionSumitomo Pharma America, Inc. · completed · Bipolar Depression · study director
- Ph4NCT01265823 · Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque PsoriasisAbbVie (prior sponsor, Abbott) · completed · Psoriasis · study director
- Ph2NCT01247675 · A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone DeficiencyAscendis Pharma A/S · completed · Adult Growth Hormone Deficiency · study director
- Ph2NCT01244425 · Fibrin Sealant VH S/D 500 S-apr in Hepatic ResectionBaxter Healthcare Corporation · completed · Bleeding (Oozing) in Hepatic Resection · study director
- Ph3NCT01143077 · A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic AgentsSumitomo Pharma America, Inc. · completed · Schizophrenia, Schizoaffective Disorder · study director
- Ph3NCT01143090 · A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective DisorderSumitomo Pharma America, Inc. · completed · Schizophrenia, Schizoaffective Disorder · study director
- Ph2NCT01063803 · Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid ArthritisAblynx, a Sanofi company · completed · Rheumatoid Arthritis · study director
- Ph1NCT01042106 · Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy AdultsSumitomo Pharma America, Inc. · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT00924703 · Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)BioMarin Pharmaceutical · completed · Phenylketonuria · study director
- Ph3NCT00868699 · Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)Sumitomo Pharma America, Inc. · completed · Bipolar Depression · study director
- Ph3NCT00868959 · Lurasidone - A 24-week Extension Study of Patients With Bipolar I DepressionSumitomo Pharma America, Inc. · completed · Bipolar Depression · study director
- Ph3NCT00868452 · Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)Sumitomo Pharma America, Inc. · completed · Bipolar Depression · study director
- N/ANCT00859287 · Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive EsophagitisAstraZeneca · completed · Reflux Esophagitis
- N/ANCT00859560 · Retrospective Survey of Bone Fracture in Patients With Arimidex 1mgAstraZeneca · completed · Breast Cancer
- Ph3NCT00809757 · A Safety, Efficacy and Tolerability Study in Pediatric Subjects With AsthmaSumitomo Pharma America, Inc. · completed · Asthma · study director
- Ph3NCT00790192 · Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.Sumitomo Pharma America, Inc. · completed · Schizophrenia · study director
- Ph3NCT00789698 · Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic SchizophreniaSumitomo Pharma America, Inc. · completed · Chronic Schizophrenia · study director
- Ph3NCT00641745 · Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable SchizophreniaSumitomo Pharma America, Inc. · completed · Schizophrenia, Schizoaffective Disorder · study director
- Ph3NCT00615433 · Lurasidone HCl A Phase 3 Study of Patients With Acute SchizophreniaSumitomo Pharma America, Inc. · completed · Schizophrenia · study director
- Ph1NCT00549666 · A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female SubjectsSumitomo Pharma America, Inc. · completed · Pharmacokinetics · study director
- Ph3NCT00549718 · Lurasidone HCl: A Phase 3 Study of Patients With Acute SchizophreniaSumitomo Pharma America, Inc. · completed · Schizophrenia · study director
- Ph2NCT00460811 · Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Ironwood Pharmaceuticals, Inc. · completed · Irritable Bowel Syndrome With Constipation · study director
- Ph3NCT00457899 · Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective DisorderAstraZeneca · terminated · Schizophrenia, Schizoaffective Disorders, Psychotic Disorders · study director
- Ph4NCT00444275 · Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsAstraZeneca · completed · GERD · study director
- Ph4NCT00391846 · Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs AloneAstraZeneca · completed · Heart Failure, Ventricular Dysfunction, Left · study director
- Ph4NCT00392002 · Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for ResponseAstraZeneca · completed · Gastroesophageal Reflux · study director
- Ph3NCT00380250 · Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With ConstipationSucampo Pharma Americas, LLC · completed · Irritable Bowel Syndrome With Constipation · study director
- Ph2NCT00359944 · Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's DiseaseSumitomo Pharma America, Inc. · completed · Alzheimer's Disease · study director
- Ph3NCT00358280 · Ropivacaine Versus Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb SurgeryAstraZeneca · completed · Anesthesia,Spinal · study director
- Ph3NCT00357734 · Iressa Follow-up TrialAstraZeneca · completed · Lung Cancer, Breast Cancer · study director
- N/ANCT00347217 · Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular EventAstraZeneca · completed · Hypercholesteremia · study director
- Ph4NCT00335699 · Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic SyndromeAstraZeneca · completed · Hypercholesterolemia · study director
- Ph2NCT00334295 · Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.AstraZeneca · completed · Endometrial Carcinoma · study director
- Ph2NCT00333294 · Phase II Iressa + Irradiation Followed by Chemo in NSCLCAstraZeneca · completed · Non-Small Cell Lung Cancer · study director
- Ph3NCT00328978 · Seroquel STACK Study in Schizophrenic or Schizoaffective SubjectsAstraZeneca · completed · Schizophrenia, Schizoaffective Disorders · study director
- Ph3NCT00325195 · Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic GoutSavient Pharmaceuticals · completed · Gout · study director
- Ph4NCT00323479 · Arthralgia During Anastrozole Therapy for Breast CancerAstraZeneca · completed · Early Breast Cancer · study director
- Ph2NCT00319618 · Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast CancerAstraZeneca · completed · Metastatic Breast Cancer · study director
- Ph4NCT00318994 · Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe PancreatitisPfizer · completed · Pancreatitis · study director
- Ph2NCT00319787 · Combination Casodex® and Iressa™ in Locally Advanced Prostate CancerAstraZeneca · completed · Locally Advanced Prostate Cancer · study director
- Ph4NCT00318552 · Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.Pfizer · completed · Sepsis · study director
- Ph2NCT00318539 · Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg StudyAstraZeneca · completed · Obsessive Compulsive Disorder · study director
- Ph3NCT00319306 · Real Life Effectiveness in Asthma of Symbicort Single Inhaler TherapyAstraZeneca · completed · Asthma · study director
- Ph3NCT00306540 · Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress DisorderAstraZeneca · completed · Post-Traumatic Stress Disorder · study director
- Ph3NCT00305422 · Effect of Quetiapine on Negative Symptoms and CognitionAstraZeneca · completed · Schizophrenia · study director
- Ph2NCT00305448 · A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgAstraZeneca · completed · Advanced Breast Cancer, Metastatic Breast Cancer · study director
- Ph3NCT00304473 · Fast Titration in the Treatment of Schizophrenia, TaiwanAstraZeneca · completed · Schizophrenia · study director
- Ph2NCT00303524 · Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal PatientsAstraZeneca · completed · Breast Cancer · study director
- Ph3NCT00302770 · Efficacy of Quetiapine in Generalised Social Anxiety DisorderAstraZeneca · terminated · Social Anxiety Disorder · study director
- Ph3NCT00301457 · Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast CancerMaastricht University Medical Center · completed · Breast Cancer · study director
- Ph3NCT00300508 · 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast CancerAstraZeneca · completed · Breast Neoplasms · study director
- Ph3NCT00296387 · Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary SyndromeAstraZeneca · completed · Acute Coronary Syndrome · study director
- Ph3NCT00295620 · Secondary Adjuvant Long Term Study With ArimidexAstraZeneca · completed · Breast Cancer · study director
- Ph3NCT00291759 · ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.AstraZeneca · completed · Breast Cancer · study director
- Ph3NCT00290264 · SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent AsthmaAstraZeneca · completed · Asthma · study director
- Ph4NCT00272753 · Effect of Budesonide / Formoterol Combination in Repeated AMP ProvocationsAstraZeneca · completed · Asthma · study director
- Ph4NCT00272701 · Esomeprazole in PPI Failures - IMPROVEAstraZeneca · completed · Gastroesophageal Reflux Disease · study director
- Ph2NCT00272740 · SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast CancerAstraZeneca · completed · Breast Neoplasms · study director
- N/ANCT00272727 · Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and CaregiverAstraZeneca · completed · Asthma · study director
- Ph2NCT00265070 · Trial of Iressa in Prostate Cancer PatientsAstraZeneca · completed · Prostate Cancer · study director
- Ph2NCT00264498 · Phase II Iressa & Carbo/Gem in NSCLCAstraZeneca · completed · Carcinoma, Non-Small-Cell Lung · study director
- Ph4NCT00262548 · C-Reactive Protein (CRP) in Obese Diabetic WomenAstraZeneca · completed · Diabetes Mellitus, Type 2 · study director
- Ph2NCT00261417 · Dose Response Study in Japanese PatientsAstraZeneca · terminated · Type 2 Diabetes · study director
- Ph3NCT00259792 · SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and AdultsAstraZeneca · completed · Asthma · study director
- Ph3NCT00259051 · A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese PopulationAstraZeneca · completed · Non-erosive Reflux Disease · study director
- Ph4NCT00255268 · CMAB vs IMAB in Metastatic Prostate CancerAstraZeneca · withdrawn · Metastatic Prostate Cancer · study director
- Ph3NCT00254813 · Fast Titration Of Quetiapine Versus Currently Approved TitrationAstraZeneca · completed · Psychotic Disorders · study director
- Ph3NCT00254735 · Quetiapine Augmentation in Severe Obsessive Compulsive DisorderAstraZeneca · completed · Obsessive Compulsive Disorder · study director
- Ph2NCT00254748 · Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered PatientsAstraZeneca · completed · Borderline Personality Disorder · study director
- Ph3NCT00254774 · Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid CyclingAstraZeneca · completed · Bipolar Disorder · study director
- Ph3NCT00252707 · Iressa 2nd Line Phase III Study in JapanAstraZeneca · completed · Non-Small Cell Lung Cancer · study director
- N/ANCT00252759 · Iressa Case Control Study in JapanAstraZeneca · completed · Non-small Cell Lung Cancer · study director
- Ph2NCT00252811 · A Study of ZD1839 Effects on Cell Proliferation in Breast CancerAstraZeneca · withdrawn · Breast Cancer · study director
- Ph1NCT00252798 · ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung CancerAstraZeneca · completed · Non Small Cell Lung Carcinoma · study director
- Ph2NCT00247481 · ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast CancerAstraZeneca · completed · Breast Cancer · study director
- N/ANCT00246961 · Arimidex Observational: Reason for and Effect of Change From TamoxifenAstraZeneca · completed · Breast Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- PREVENT - Practice-based Approaches to Promote HPV VaccinationR01CA279973 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Deanna Lee Kepka · fiscal years 2023 to 2026Named on NCT06290206
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.